|
ES2221717T3
(es)
|
1997-12-08 |
2005-01-01 |
Emd Lexigen Research Center Corp. |
Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
|
|
US6566500B1
(en)
|
1999-03-30 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinaceous compounds
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
WO2001010912A1
(en)
|
1999-08-09 |
2001-02-15 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
CA2391080A1
(en)
|
1999-11-12 |
2001-05-25 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Erythropoietin forms with improved properties
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
EP1935431A3
(de)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
|
|
US6689353B1
(en)
*
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
CZ2003214A3
(cs)
|
2000-06-29 |
2003-08-13 |
Merck Patent Gmbh |
Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
|
|
US7723102B2
(en)
*
|
2000-09-28 |
2010-05-25 |
Bayer Corporation |
Enhanced transfection system
|
|
MY139948A
(en)
*
|
2000-09-28 |
2009-11-30 |
Bayer Corp |
Enhanced transfection system
|
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
EP1454138B1
(de)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokine mit modulierter selektivität
|
|
ATE471946T1
(de)
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
ES2356154T3
(es)
*
|
2003-07-21 |
2011-04-05 |
Transgene S.A. |
Citoquinas multifuncionales.
|
|
DE602004031341D1
(de)
*
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
AU2004287879C1
(en)
|
2003-11-04 |
2011-05-26 |
Novartis Vaccines And Diagnostics, Inc. |
Antagonist anti-CD40 monoclonal antibodies and methods for their use
|
|
ES2367027T3
(es)
*
|
2004-02-27 |
2011-10-27 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
|
|
KR20070003934A
(ko)
*
|
2004-03-05 |
2007-01-05 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
|
|
WO2009061853A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
CN101244261B
(zh)
*
|
2008-03-10 |
2010-09-15 |
山东大学 |
一种含未复性重组蛋白的生物制剂及其制备方法与应用
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
CN102101885B
(zh)
*
|
2010-09-01 |
2013-06-05 |
南京发士达生物科技有限公司 |
低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
WO2012088446A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
CN105440123B
(zh)
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
|
WO2012119093A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
JP6640834B2
(ja)
|
2014-08-11 |
2020-02-05 |
デリニア， インコーポレイテッド |
自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
PT3328894T
(pt)
*
|
2015-08-06 |
2019-02-13 |
Agency Science Tech & Res |
Anticorpos de cadeia comum gama/il2rbeta
|
|
WO2017062832A1
(en)
|
2015-10-08 |
2017-04-13 |
Nektar Therapeutics |
Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR20240115933A
(ko)
*
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
US12202856B2
(en)
|
2016-05-19 |
2025-01-21 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
IL263874B2
(en)
*
|
2016-06-22 |
2025-02-01 |
David Klatzmann |
Genetically modified T lymphocytes
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
EP3538548A4
(de)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
Il-2-varianten zur behandlung von autoimmunerkrankungen
|
|
CN110177564A
(zh)
*
|
2016-12-13 |
2019-08-27 |
德里尼亚公司 |
多价的调节t细胞调节剂
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
JOP20190271A1
(ar)
*
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
US20200362058A1
(en)
*
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
IL321812A
(en)
*
|
2017-08-03 |
2025-08-01 |
Synthorx Inc |
Cytokine complexes for the treatment of autoimmune diseases
|
|
KR102777151B1
(ko)
*
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
EP3752178A1
(de)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Verwendung von interleukin 2 zur behandlung des sjögren-syndroms
|
|
US12565525B2
(en)
|
2018-03-28 |
2026-03-03 |
Ascendis Pharma Oncology Division A/S |
IL-2 conjugates
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
US12522640B2
(en)
*
|
2018-07-24 |
2026-01-13 |
BioNTech SE |
IL2 agonists
|
|
EP3836954B1
(de)
|
2018-08-13 |
2025-05-07 |
Iltoo Pharma |
Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon
|
|
SG11202005873QA
(en)
*
|
2018-09-17 |
2020-07-29 |
Gi Innovation Inc |
Fusion protein comprising il-2 protein and cd80 protein, and use thereof
|
|
CA3098930A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
CN112105634B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
TW202034945A
(zh)
|
2018-12-21 |
2020-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種人白細胞介素２變體或其衍生物
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
TW202115105A
(zh)
*
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Ｒｎａ製藥有限公司 |
Ｉｌ２激動劑
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
CN114555634B
(zh)
|
2019-08-13 |
2025-01-10 |
美国安进公司 |
用于扩增调节性t细胞的白介素-2突变蛋白
|
|
US20230036793A1
(en)
|
2019-12-12 |
2023-02-02 |
Iltoo Pharma |
Interleukin 2 chimeric constructs
|
|
PE20221506A1
(es)
|
2019-12-17 |
2022-10-04 |
Amgen Inc |
Agonista doble de interleucina-2/receptor de tnf para uso en terapia
|
|
KR20220140514A
(ko)
|
2020-01-10 |
2022-10-18 |
브라이트 피크 테라퓨틱스 아게 |
변형된 il-2 폴리펩타이드 및 그의 용도
|
|
MX2022008770A
(es)
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Muteinas de la il2.
|
|
CN115362168A
(zh)
|
2020-01-14 |
2022-11-18 |
辛德凯因股份有限公司 |
偏向化il2突变蛋白方法和组合物
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
KR20220155316A
(ko)
|
2020-03-19 |
2022-11-22 |
이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 |
인터루킨-2 돌연변이 및 이의 용도
|
|
AR121713A1
(es)
|
2020-03-31 |
2022-06-29 |
Hanmi Pharm Ind Co Ltd |
Nuevos análogos de il-2 inmunoestimulantes
|
|
CA3178074A1
(en)
|
2020-06-03 |
2021-12-09 |
Nina Gunnarsson |
Il-2 sequences and uses thereof
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
US20240325495A1
(en)
|
2020-10-29 |
2024-10-03 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
CA3203977A1
(en)
|
2020-12-04 |
2022-06-09 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
CN113308477A
(zh)
*
|
2021-04-08 |
2021-08-27 |
华南农业大学 |
一种鸭il-2基因真核表达重组质粒及其制备方法
|
|
MX2024001877A
(es)
|
2021-08-10 |
2024-02-28 |
Kymab Ltd |
Tratamiento de dermatitis atopica.
|
|
JP7864826B2
(ja)
|
2021-09-22 |
2026-05-25 |
フォートビタ バイオロジクス（シンガポール）プライベート リミティド |
インターロイキン２変異体およびその融合タンパク質
|
|
CN118414160A
(zh)
|
2021-10-06 |
2024-07-30 |
艾尔图制药公司 |
对发炎组织具有靶向特异性的白介素2嵌合构建体
|
|
TW202333772A
(zh)
|
2021-12-01 |
2023-09-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
|
CN114875069B
(zh)
*
|
2022-04-22 |
2023-09-15 |
四川大学 |
基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
|
|
IL317511A
(en)
|
2022-06-16 |
2025-02-01 |
Cephalon Llc |
IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
|
|
AU2022477937A1
(en)
|
2022-09-12 |
2025-04-10 |
Assistance Publique - Hôpitaux De Paris |
Interleukin-2 for use in treating autism spectrum disorder
|
|
FR3140287B1
(fr)
|
2022-10-03 |
2025-11-21 |
Arkema France |
Procede de granulation de composes azoiques et granules obtenus
|
|
JP2026505714A
(ja)
|
2022-11-18 |
2026-02-18 |
ナンジン ノボアシン バイオテクノロジー カンパニー，リミテッド |
受容体親和性選好を有する部位特異的結合型ｐｅｇ化インターロイキン－２変異体及びその用途
|
|
WO2026159300A1
(en)
|
2025-01-24 |
2026-07-30 |
Iltoo Pharma |
M3c65 antibody and derivatives thereof for targeting inflammation
|